1250 Omega-3

1. Berger et al. “Metabolic and nutritional support in acute cardiac failure.” Curr Opin Clin Nutr Metab Care. 2003 Mar; 6(2):195-201
2. Nair SS, et al. “Prevention of cardiac arrhythmia by dietary (n-3) polyunsaturated fatty acids and their mechanism of action.” J Nutr. 1997 Mar;127(3):383-93
3. De Caterina R. et al. “Antiarrhythmic effects of omega-3 fatty acids: from epidemiology to bedside.”. Am Heart J. 2003 Sep;146(3):420-30
4. Bucher HC, et al. “N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials.” Am J Med. 2002;112:298-304
5. Supari F., et al. “Fish oil treatment decreases superoxide anions in the myocardium and coronary arteries of atherosclerotic monkeys.” Circulation. 1995 Feb 15;91(4):1123-8
6. Richter WO., et al. “Long-chain omega-3 fatty acids from fish reduce sudden cardiac death in patients with coronary heart disease.” Eur J Med Res. 2003 Aug 20;8(8):332-6
7. Yli-Jama P. “Serum-free fatty acid pattern and risk of myocardial infarction: a case-control study.” J Intern Med. 2002 Jan;251(1):19-28
8. Mozaffarian D, et al. “Effect of Fish Oil on Heart Rate in Humans…” Circulation. 2005 Sep 19 [Epub ahead of print]
9. Paillard F. “Nutritional counseling for coronary and hypertensive patients.” Arch Mal Coeur Vaiss. 2003 Sep;96:27-33
10. Armitage JA. “Increased blood pressure later in life may be associated with perinatal n-3 fatty acid deficiency.” Lipids. 2003 Apr;38(4):459-64
11. Mori TA. et al. “Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans.” Hypertension. 1999;34:253-260
12. Frenoux JM. et al. “A polyunsaturated fatty acid diet lowers blood pressure and improves antioxidant status in spontaneously hypertensive rats.” J Nutr. 2001 Jan;131(1):39-45
13. Rousseau et al. “Dietary n-3 polyunsaturated fatty acids affect the development of renovascular hypertension in rats.”. Mol Cell Biochem. 2001 Sep;225(1-):109-19
14. Morris MCB. “Does fish oil lower blood pressure? A meta-analysis of controlled trials.” Circulation 1993
15. Curtis CL. “Effects of n-3 fatty acids on cartilage metabolism.” Proc Nutr Soc. 2002 Aug;61(3):381-9
16. James MJ et al. “Dietary omega-3 fats as adjunctive therapy in a prototypic inflammatory disease: issues and obstacles for use in rheumatoid arthritis.” Prostaglandins Leukot Essent Fatty Acids. 2003 Jun;68(6):399-405
17. Simopoulos AP. “Omega-3 fatty acids in inflammation and autoimmune diseases.” J Am Coll Nutr. 2002 Dec;21(6):495-505
18. Cleland LG. “The role of fish oils in the treatment of rheumatoid arthritis.” Drugs. 2003;63(9):845-53
19. Durrington PN, et al. “An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia.” Heart. 2001;85:544–548
20. “The effect of a diet enriched with omega-3 polyunsaturated fatty acids on the indices of the blood fibrinolytic system in patients in the initial stages of ischemic heart disease.” Kardiologiia. 1993;33(6):21-5
21. Saynor R. et al. “The long-term effect of dietary supplementation with fish lipid concentrate on serum lipids, bleeding time, platelets, and angina.” Atherosclerosis. 1984 Jan;50(1):3-10
22. Menendez JA. “Overexpression and hyperactivity of breast cancer associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues, but it is selectively inhibited by tumoricidal alpha-linolenic and gammalinolenic fatty acids…” Int J Oncol. 2004 Jun;24.)
23. Nkondjock A. “Intake of specific carotenoids and essential fatty acids and breast cancer risk in Montreal, Canada.” Am J Clin Nutr. 2004 May;79
24. Jordan A. “Effect of an omega-3 fatty acid containing lipid emulsion alone and in combination with 5-fluorouracil (5-FU) on growth of the colon cancer cell line Caco-2.” Eur J Nutr. 2003 Dec;42(6):324-31
25. Hardman WE, et al. “Consumption of an omega-3 fatty acids product, INCELL AAFA, reduced side-effects of CPT-11 (irinotecan) in mice.” Br J Cancer. 2002;86:983-988
26. Holness MJ. “Acute omega-3 fatty acid enrichment selectively reverses high-saturated fat feeding-induced insulin hypersecretion but does not improve peripheral insulin resistance.” Diabetes. 2004 Feb;53 Suppl 1
27. Simoncikova P. “Comparison of the extrapancreatic action of gammalinolenic acid and n-3 PUFAs in the high fat diet-induced insulin resistance [corrected].” Endocr Regul. 2002 Nov;36 28. Shimura T. “Docosahexanoic acid (DHA) improved glucose and lipid metabolism in KK-Ay mice with genetic non-insulin-dependent diabetes mellitus (NIDDM).” Biol Pharm Bull. 1997 May;20
28. Holness MJ. “Diabetogenic impact of long-chain omega-3 fatty acids on pancreatic beta-cell function and the regulation of endogenous glucose production.” Endocrinology. 2003 Sep;1
29. “Resistance to Leptin Contributes to Obesity.” The Rockefeller University. 1997, Aug. 5
30. Kruger MC, et al. “Calcium, gamma-linolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis.” Aging (Milano).1998;10:385–394
31. Albertazzi P, et al. “Polyunsaturated fatty acids. Is there a role in postmenopausal osteoporosis prevention?” Maturitas. 2002 May 20;42(1):13-22
32. Terano T. “Effect of omega 3 polyunsaturated fatty acid ingestion on bone metabolism and osteoporosis.” World Rev Nutr Diet. 2001;88:141-7
33. Högström, M et al. “n–3 Fatty acids are positively associated with peak bone mineral density and bone accrual in healthy men: the NO2 Study.” Am J Clin Nutr. 2007 85: 803-807
34. Morris MC. “Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease.” Arch Neurol. 2003 Jul;60
35. Hashimoto M. “Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer’s disease model rats.” J Neurochem. 2002 Jun;81
36. Farooqu AA. “Plasmalogens, phospholipase A2, and docosahexaenoic acid turnover in brain tissue.” J Mol Neurosci. 2001 Apr-Jun;16.
37. Malcolm Peet. “Essential fatty acids theoretical aspects and treatment implications for schizophrenia and depression.” Advances in Psychiatric Treatment 2002; 8 223-229
38. Murck H. “Ethyl-eicosapentaenoate and dexamethasone resistance in therapy-refractory depression.” Int J Neuropsychopharmacol. 2004 Jun;:1-9
39. Nemets B, et al. “Addition of Omega-3 Fatty Acid to Maintenance Medication Treatment for Recurrent Unipolar Depressive Disorder.” American Journal of Psychiatry 2002;159 477-479
40. Tsekos E. “Perioperative administration of parenteral fish oil supplements in a routine clinical setting improves patient outcome after major abdominal surgery.” Clin Nutr. 2004 Jun;23
41. Switzer KC. (n-3) Polyunsaturated fatty acids promote activation-induced cell death in murine T lymphocytes.” J Nutr. 2003 Feb;133
42. Walton AJE, et al. “Dietary fish oil and the severity of symptoms in patients with systemic lupus erythematosus.” Ann Rheum Dis. 1991;50:463–466
43. Cho E, et al. “Prospective study of dietary fat and the risk of age-related macular degeneration.” Am J Clin Nutr. 2001 Feb;73(2):209-18
44. Seddon JM, et al. “Dietary fat and risk for advanced age-related macular degeneration.” Arch Opthalmol. 2001;119(8):1191-1199
45. Seddon JM. “Progression of age-related macular degeneration: association with dietary fat, trans-unsaturated fat, nuts, and fish intake.” Arch Ophthalmol. 2003 Dec;121(12):1728-37

1250+ Omega-3 w/ Vitamin D3

1. Berger et al. “Metabolic and nutritional support in acute cardiac failure.” Curr Opin Clin Nutr Metab Care. 2003 Mar; 6(2):195-201
2. Nair SS, et al. “Prevention of cardiac arrhythmia by dietary (n-3) polyunsaturated fatty acids and their mechanism of action.” J Nutr. 1997 Mar;127(3):383-93
3. De Caterina R. et al. “Antiarrhythmic effects of omega-3 fatty acids: from epidemiology to bedside.”. Am Heart J. 2003 Sep;146(3):420-30
4. Bucher HC, et al. “N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials.” Am J Med. 2002;112:298-304
5. Supari F., et al. “Fish oil treatment decreases superoxide anions in the myocardium and coronary arteries of atherosclerotic monkeys.” Circulation. 1995 Feb 15;91(4):1123-8
6. Richter WO., et al. “Long-chain omega-3 fatty acids from fish reduce sudden cardiac death in patients with coronary heart disease.” Eur J Med Res. 2003 Aug 20;8(8):332-6
7. Yli-Jama P. “Serum-free fatty acid pattern and risk of myocardial infarction: a case-control study.” J Intern Med. 2002 Jan;251(1):19-28
8. Mozaffarian D, et al. “Effect of Fish Oil on Heart Rate in Humans…” Circulation. 2005 Sep 19 [Epub ahead of print]
9. Paillard F. “Nutritional counseling for coronary and hypertensive patients.” Arch Mal Coeur Vaiss. 2003 Sep;96:27-33
10. Armitage JA. “Increased blood pressure later in life may be associated with perinatal n-3 fatty acid deficiency.” Lipids. 2003 Apr;38(4):459-64
11. Mori TA. et al. “Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans.” Hypertension. 1999;34:253-260
12. Frenoux JM. et al. “A polyunsaturated fatty acid diet lowers blood pressure and improves antioxidant status in spontaneously hypertensive rats.” J Nutr. 2001 Jan;131(1):39-45
13. Rousseau et al. “Dietary n-3 polyunsaturated fatty acids affect the development of renovascular hypertension in rats.”. Mol Cell Biochem. 2001 Sep;225(1-):109-19
14. Morris MCB. “Does fish oil lower blood pressure? A meta-analysis of controlled trials.” Circulation 1993
15. Curtis CL. “Effects of n-3 fatty acids on cartilage metabolism.” Proc Nutr Soc. 2002 Aug;61(3):381-9
16. James MJ et al. “Dietary omega-3 fats as adjunctive therapy in a prototypic inflammatory disease: issues and obstacles for use in rheumatoid arthritis.” Prostaglandins Leukot Essent Fatty Acids. 2003 Jun;68(6):399-405
17. Simopoulos AP. “Omega-3 fatty acids in inflammation and autoimmune diseases.” J Am Coll Nutr. 2002 Dec;21(6):495-505
18. Cleland LG. “The role of fish oils in the treatment of rheumatoid arthritis.” Drugs. 2003;63(9):845-53
19. Durrington PN, et al. “An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia.” Heart. 2001;85:544–548
20. “The effect of a diet enriched with omega-3 polyunsaturated fatty acids on the indices of the blood fibrinolytic system in patients in the initial stages of ischemic heart disease.” Kardiologiia. 1993;33(6):21-5
21. Saynor R. et al. “The long-term effect of dietary supplementation with fish lipid concentrate on serum lipids, bleeding time, platelets, and angina.” Atherosclerosis. 1984 Jan;50(1):3-10
22. Menendez JA. “Overexpression and hyperactivity of breast cancer associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues, but it is selectively inhibited by tumoricidal alpha-linolenic and gammalinolenic fatty acids…” Int J Oncol. 2004 Jun;24.)
23. Nkondjock A. “Intake of specific carotenoids and essential fatty acids and breast cancer risk in Montreal, Canada.” Am J Clin Nutr. 2004 May;79
24. Jordan A. “Effect of an omega-3 fatty acid containing lipid emulsion alone and in combination with 5-fluorouracil (5-FU) on growth of the colon cancer cell line Caco-2.” Eur J Nutr. 2003 Dec;42(6):324-31
25. Hardman WE, et al. “Consumption of an omega-3 fatty acids product, INCELL AAFA, reduced side-effects of CPT-11 (irinotecan) in mice.” Br J Cancer. 2002;86:983-988
26. Holness MJ. “Acute omega-3 fatty acid enrichment selectively reverses high-saturated fat feeding-induced insulin hypersecretion but does not improve peripheral insulin resistance.” Diabetes. 2004 Feb;53 Suppl 1
27. Simoncikova P. “Comparison of the extrapancreatic action of gammalinolenic acid and n-3 PUFAs in the high fat diet-induced insulin resistance [corrected].” Endocr Regul. 2002 Nov;36 28. Shimura T. “Docosahexanoic acid (DHA) improved glucose and lipid metabolism in KK-Ay mice with genetic non-insulin-dependent diabetes mellitus (NIDDM).” Biol Pharm Bull. 1997 May;20
28. Holness MJ. “Diabetogenic impact of long-chain omega-3 fatty acids on pancreatic beta-cell function and the regulation of endogenous glucose production.” Endocrinology. 2003 Sep;1
29. “Resistance to Leptin Contributes to Obesity.” The Rockefeller University. 1997, Aug. 5
30. Kruger MC, et al. “Calcium, gamma-linolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis.” Aging (Milano).1998;10:385–394
31. Albertazzi P, et al. “Polyunsaturated fatty acids. Is there a role in postmenopausal osteoporosis prevention?” Maturitas. 2002 May 20;42(1):13-22
32. Terano T. “Effect of omega 3 polyunsaturated fatty acid ingestion on bone metabolism and osteoporosis.” World Rev Nutr Diet. 2001;88:141-7
33. Högström, M et al. “n–3 Fatty acids are positively associated with peak bone mineral density and bone accrual in healthy men: the NO2 Study.” Am J Clin Nutr. 2007 85: 803-807
34. Morris MC. “Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease.” Arch Neurol. 2003 Jul;60
35. Hashimoto M. “Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer’s disease model rats.” J Neurochem. 2002 Jun;81
36. Farooqu AA. “Plasmalogens, phospholipase A2, and docosahexaenoic acid turnover in brain tissue.” J Mol Neurosci. 2001 Apr-Jun;16.
37. Malcolm Peet. “Essential fatty acids theoretical aspects and treatment implications for schizophrenia and depression.” Advances in Psychiatric Treatment 2002; 8 223-229
38. Murck H. “Ethyl-eicosapentaenoate and dexamethasone resistance in therapy-refractory depression.” Int J Neuropsychopharmacol. 2004 Jun;:1-9
39. Nemets B, et al. “Addition of Omega-3 Fatty Acid to Maintenance Medication Treatment for Recurrent Unipolar Depressive Disorder.” American Journal of Psychiatry 2002;159 477-479
40. Tsekos E. “Perioperative administration of parenteral fish oil supplements in a routine clinical setting improves patient outcome after major abdominal surgery.” Clin Nutr. 2004 Jun;23
41. Switzer KC. (n-3) Polyunsaturated fatty acids promote activation-induced cell death in murine T lymphocytes.” J Nutr. 2003 Feb;133
42. Walton AJE, et al. “Dietary fish oil and the severity of symptoms in patients with systemic lupus erythematosus.” Ann Rheum Dis. 1991;50:463–466
43. Cho E, et al. “Prospective study of dietary fat and the risk of age-related macular degeneration.” Am J Clin Nutr. 2001 Feb;73(2):209-18
44. Seddon JM, et al. “Dietary fat and risk for advanced age-related macular degeneration.” Arch Opthalmol. 2001;119(8):1191-1199
45. Seddon JM. “Progression of age-related macular degeneration: association with dietary fat, transunsaturated fat, nuts, and fish intake.” Arch Ophthalmol. 2003 Dec;121(12):1728-37

GlycoMarine

1. Winter CA, Risley EA & Nuss GW, Carrageenin Induced Oedema in Hind Paw of the Rat as an Assay for Anti-inflammatory Drugs. Proc Soc Exp Biol Med 111:544-547 (1962).
2. Ormrod DJ & Miller TE, Assessment of Anti-inflammatory Agents Using 1251 Labeled Human Serum Albumin to Quantify Footpad Oedema Volume in the Rat. Pharm Res, 8: 1270-1273 (1991).
3. Gibson RG, Gibson SLM, Conway V & Chappell D. Perna Canalliculus in the treatment of Arthritis. The Practitioner, 224, 995-999, (1980)
4. Rainsford KD & Whitehouse MW. Gastro-protective and Anti-inflammatory Properties of Green Lipped Mussel. (Perna canaliculus) Preparation. Arzneim-Forsch. /Drug Research, 30(11), 2128-2132, (1980).
5. Miller TE & Ormrod D. The Anti-inflammatory Activity of Perna Canaliculus (NZ green lipped mussel). New Zealand Medical Journal, 667, 187-193 (1980).
6. Couch RAF, Ormrod DJ, Miller TE & Watkins WB. Anti-inflammatory Activity in Fractionated Extracts of the Green-Lipped Mussel. New Zealand Medical Journal, 720, 803-806 (1982).
7. Miller TE & Wu H. In Vivo Evidence for Prostaglandin Inhibitory Activity in New Zealand Green-Lipped Mussel Extract. New Zealand Medical Journal, 755, 355-357 (1984).
8. Billard H. Extract of Perna Canaliculus (New Zealand Green-Lipped Mussel) in Rheumatology. La Gazette Medicale, 92(7), 1-5, 1985.
9. Audeval B & Bouchacourt P. Double blind, placebo controlled study of the Mussel Perna Canaliculus (New Zealand Green-Lipped Mussel) in Gonarthritis (arthritis of the knee). La Gazette Medicale, 93 (38), 1986.
10. Kosuge T, Tsuji K, Ishida H & Yamaguchi T. Isolation of an Anti-histamine Substance from Green-Lipped Mussel (Perna Canaliculus). Chem. Pharm. Bull, 34, 4825-4828, 1986.
11. Miller TE, Dodd J., Ormrod D & Geddes R. Anti-inflammatory Activity of Glycogen Extracted from Perna canaliculus (NZ Green-Lipped Mussel). Agents and actions, 38, C139-C142, 1993.
12. Ormrod DJ, Dodd JR, Geddes R & Miller TE. Demonstration and Characterization of anti-inflammatory activity in a carbohydrate (glycogen) extract of the New Zealand green-lipped mussel (Perna canaliculus). Proceedings of the 6th International Congress of the European Association for Veterinary Pharmacology and Therapeutics, Blackwell Scientific Publications, p160, 1994.

Heart360 Multivitamin

1. den Heijer M, Brouwer IA, Bos GM, Blom HJ, van der Put NM, Spaans AP, Rosendaal FR, Thomas CM, Haak HL, Wijermans PW, Gerrits WB. Department of Hematology, Leyenburg Hospital, The Hague, The Netherlands. Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers. Arterioscler Thromb Vasc Biol. 1998 Mar;18(3):356-61.
2. Yan Ji, MD, Song Tan, MD, Yuming Xu, MD, Avinash Chandra, MD, Changhe Shi, MD, Bo Song, MD, Jie Qin, MD and Yuan Gao, MD. Vitamin B supplementation, homocysteine levels, and the risk of cerebrovascular disease. A meta-analysis. Published online before print September 18, 2013, doi: 10.1212/WNL.0b013e3182a823cc Neurology 10.1212/WNL.0b013e3182a823cc

Ideal Weight

1. Kudiganti V, Kodur RR, Kodur SR, Halemane M, Deep DK. Efficacy and tolerability of Meratrim for weight management: a randomized, double-blind, placebo-controlled study in healthy overweight human subjects. Lipids Health Dis. 2016 Aug 24;15(1):136. doi: 10.1186/s12944-016-0306-4. PMID: 27558585; PMCID: PMC4997756.
2. Saiyed ZM, Sengupta K, Krishnaraju AV, Trimurtulu G, Lau FC, Lugo JP. Safety and toxicological evaluation of Meratrim®: an herbal formulation for weight management. Food Chem Toxicol. 2015 Apr;78:122-9. doi: 10.1016/j.fct.2015.02.010. Epub 2015 Feb 11. PMID: 25680508.
3. Lai C S, Liao S N, Tsai M L, Kalyanam N, Majeed M, Majeed A & Pan M H. (2015). Calebin‐A inhibits adipogenesis and hepatic steatosis in high‐fat diet‐induced obesity via activation of AMPK signaling. Molecular Nutrition & Food research, 59(10), 1883-1895.
4. Sengupta K, Mishra AT, Rao MK, Sarma KV, Krishnaraju AV, Trimurtulu G. Efficacy and tolerability of a novel herbal formulation for weight management in obese subjects: a randomized double-blind placebo-controlled clinical study. Lipids Health Dis. 2012 Sep 20;11:122. doi: 10.1186/1476-511X-11-122. PMID: 22995673; PMCID: PMC3492046.
5. Sengupta K, Golakoti T, Chirravuri VR, Marasetti AK. An herbal formula LI85008F inhibits lipogenesis in 3T3-L1 adipocytes. Food Nutr Sci. 2011;2:809–817. doi: 10.4236/fns.2011.28111.
6. Dixit K, Kamath DV, Alluri KV, Davis BA. Efficacy of a novel herbal formulation for weight loss demonstrated in a 16-week randomized, double-blind, placebo-controlled clinical trial with healthy overweight adults. Diabetes Obes Metab. 2018 Nov;20(11):2633-2641. doi: 10.1111/dom.13443. Epub 2018 Jul 18. PMID: 29923305.
7. Lee PS, Lu YY, Nagabhushanam K, Ho CT, Mei HC, Pan MH. Calebin-A prevents HFD-induced obesity in mice by promoting thermogenesis and modulating gut microbiota. J Tradit Complement Med. 2022 Jan 5;13(2):119-127. doi: 10.1016/j.jtcme.2022.01.001. PMID: 36970457; PMCID: PMC10037069.
8. Celleno L, Tolaini MV, D'Amore A, Perricone NV, Preuss HG. A Dietary supplement containing standardized Phaseolus vulgaris extract influences body composition of overweight men and women. Int J Med Sci. 2007 Jan 24;4(1):45-52. doi: 10.7150/ijms.4.45. PMID: 17299581; PMCID: PMC1796956.
9. Preuss HG. Bean amylase inhibitor and other carbohydrate absorption blockers: effects on diabesity and general health. J Am Coll Nutr. 2009 Jun;28(3):266-76. doi: 10.1080/07315724.2009.10719781. PMID: 20150600.
10. Udani J, Singh BB. Blocking carbohydrate absorption and weight loss: a clinical trial using a proprietary fractionated white bean extract. Altern Ther Health Med. 2007 Jul-Aug;13(4):32-7. PMID: 17658120.
11. Majeed M, Nagabhushanam K, Devarajan TV, Saklecha S, Reddy SVK, Mundkur L. A minor metabolite from Curcuma longa effective against metabolic syndrome: results from a randomized, double-blind, placebo-controlled clinical study. Food Funct. 2023 May 22;14(10):4722-4733. doi: 10.1039/d2fo03627d. PMID: 37114318.

Land 'n' Sea Fiber

1. Shrestha S, Freake HC, McGrane MM, Volek JS, Fernandez ML. A combination of psyllium and plant sterols alters lipoprotein metabolism in hypercholesterolemic subjects by modifying the intravascular processing of lipoproteins and increasing LDL uptake. J Nutr 2007 May;137(5):1165-1170.

LDL-XQ10 (Red Yeast Rice w/ CoQ10)

1. Becker D, Gordon R, Morris P, Yorko J, Gordon Y, Li M, Iqbal N. Simvastatin vs Therapeutic Lifestyle Changes and Supplements: Randomized Primary Prevention Trial. Mayo Clin Proc July 2008;83(7):758-764.
2. Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med. 2009;150(12):830-9.
3. Cunningham E. Is Red Yeast Rice Safe and Effective for Lowering Serum Cholesterol? J Am Diet Assoc 2011 Feb.;111(2):324.
4. Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T, Fønnebø V. Chinese red yeast rice(Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med 2006;1(1):4.
5. Lu Z, Kou W, Du B, Wu Y, Zhao S. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. The American journal of … 2008;
6. Halbert SC, French B, Gordon RY, et al. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol 2010 Jan.;105(2):198-204.
7. Gordon RY, Cooperman T, Obermeyer W, Becker DJ. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! Arch Intern Med 2010 Oct.;170(19):1722-1727.
8. Heber D, Yip I, Ashley JM, et al. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 1999;69:231–6.
9. Bonovich, K, Colfer H, Davidson M, Dujovne C, Greenspan M, Karlberg R, et al. A Multi-Center, Self-Controlled Study of Cholestin In Subjects With Elevated Cholesterol. American Hear Association. 39th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, Orlando, Fl. March 1999.
10. Huang CF, Li TC, Lin CC, Liu CS, Shih HC, Lai MM. Efficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients. Eur J Cardiovasc Prev Rehabil. 2007 Jun;14(3):438-40.
11. Li C, Zhu Y, Wang Y, Zhu J, Chang J, Kritchevsky D. Monascus Purpureus-Fermented Rice (Red Yeast Rice): A natural food product that lowers blood cholesterol in animal models of hypercholesterolemia. Nutrition Research. 1998;18(1):71-81.
12. Mark D. All red yeast rice products are not created equal. The Am J of Cardiol. 106(3).
13. Ong HT, Cheah JS. Statin alternatives or just placebo: an objective review of omega-3, red yeast rice and garlic in cardiovascular therapeutics. Chin Med J (Engl). 2008 Aug 20;121(16):1588-94.
14. Qin S, Zhang W, Qi P, Zhao M, Dong Z, Li Y , et al. Elderly patients with primary hyperlipidemia benefited from treatment with a Monacus purpureus rice preparation: A placebo-controlled, double-blind clinical trial. American Heart Association. 39th Annual conference on Cardiovascular Disease Epidemiology and Prevention, Orlando, Fl. March 1999.
15. Wang J, Lu Z, Chi J, Wang W, Su M, Kou W, et al. Multicenter clinical trial of serum lipid-lowering effects of a Monascus purpureus (red yeast) rice preparation from traditional Chinese medicine. Curr Ther Res. 1997;58(12):964-978.
16. Venero C, Venero J, Wortham D, Thompson P. Lipid-lowering efficacy of red yeast rice in a population intolerant to statins. The Am J Cardiol. 1-5(5).

MetaboLOCK

1. Metabolic syndrome management and weight reductions using enhanced LeptiPURE™ at 500 mg per day for 60 days. (Published in Patent 8,936,817, Issued January 20, 2015).
2. GymnePURE® effects on C-reactive protein and Glycosylated Hemoglobin (HbA1c) status of diabetic patients. Ayurvedic Life International. Salt Lake March 26, 2011.
3. Relative Studies On Different Diabetic Patients Administered With GymnePURE®, Insulin And OH (Oral Hypoglycemic Drug, Metformin) Separately. University Kolkata, India November 12, 2010.
4. Metabolic syndrome management and weight reductions using enhanced LeptiPURE™ at 1000mg per day for 60 days. (Published in Patent 8,936,817, Issued January 20, 2015).
5. Gymnema Sylvestre Extracts Stimulate Insulin Secretion in Vitro and in Vivo: a Potential Phytopharmacological Therapy for Type 2 Diabetes. American Diabetes Association, Abstract Book, 67th Scientific Sessions, Friday, June 22 - Tuesday, June 26, 2007.
6. Biological properties of citrus flavonoids pertaining to cancer and inflammation. Curr Med Chem. 2000;8(2):135-153.
7. Structure and hypotensive effect of flavonoid glycosides in orange (Citrus sinensis OSBECK) peelings. Agric Biol Chem. 1986;50(3):781-783.
8. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem. 1993;268(15):11230-11238.
9. Anti-cancer and cholesterol-lowering activities of tocotrienols. In: Wildman REC, ed. Handbook of Nutraceuticals and Functional Foods. Boca Raton, FL: CRC Press; 2000:269-280.
10. Effect of gamma-tocotrienol on blood pressure, lipid peroxidation and total antioxidant status in spontaneously hypertensive rats (SHR). Clin Exper Hypertens. 1999;21(8):1297-1313.
11. Tocotrienol: a review of its therapeutic potential. Clin Biochem. 1999;32(5):309-319.
12. Biological properties of citrus flavonoids pertaining to cancer and inflammation. Curr Med Chem. 2001;8(2):135-153.
13. An inhibitor of the microsomal triglyceride transfer protein inhibits apoB secretion from HepG2 cells. Proc Natl Acad Sci U S A. 1996;93(21):11991-11995.
14. Recent advances in elucidating the role of the microsomal triglyceride transfer protein in apolipo-protein B lipoprotein assembly. Curr Opin Lipidol. 1997;8(3):131-137.
15. Modulation of HepG2 cell net apolipoprotein B secretion by the citrus polymethoxy flavone, tangeretin. Lipids. 2004;39(2):143-151.
16. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem. 1993;268(15):11230-11238.
17. Hypercholesterolemic activity of synthetic and natural tocotrienols. J Med Chem. 1992;35(20):3595-3606.
18. Dietary alpha-tocopherol attenuates the impact of gamma-tocotrienol on Hepatic 3-hydroxy- 3-methylglutaryl coenzyme A reductase activity in chickens. J Nutr. 1996;126(2):389-394.
19. Tocotrienol: a review of its therapeutic potential. Clin Biochem. 1999;32(5):309-319.
20. A Novel Gymnema Sylvestre Extract Stimulates Insulin Secretion from Human Islets In Vivo and In Vitro”. Phytother. Res. 24: 1370–1376 (2010).
21. Effects of citrus flavonoids and tocotrienols on serum cholesterol levels in hypercholesterolemic subjects. Altern. Ther. in Health and Med. Nov-Dec 2007 (13). NO 6:44-48.
22. Clinical trials with Gymnema sylvestre extract on Type II Diabetics mellitus (500mg per day). Ayurvedic Life International, July, 2007.
23. Hypocholesterolemic effects of dietary citrus juices in rabbits. Nutr Res. 2000;20:121-129.
24. Clinical trials with Gymnema sylvestre extract on Type II Diabetics mellitus (Phase II study-1000 mg per day). Neenah, 2007.
25. Further Placebo Studies on Studies with Double-blind Placebo capsules of OSA administering 1000 mg/day with thirteen volunteers conducted during 2007– 2008. Ayurvedic, College & Hospital, 2008.

Res-Q MetaboLOCK's formula is protected by a portfolio of intellectual property, including four patents on Cholesstrinol™ HPe, two patents on GymnePURE® and one patent on Tinospora cordifolia. There are also multiple patents issued worldwide:

1. US Patent #6,987,125: “Compositions and methods of treating, reducing, and preventing cardiovascular disease and disorders with Polymethoxylated flavones”
2. US Serial #61/726,804: “Composition containing red yeast rice, Polymethoxylated flavones, tocotrienols, and coenzyme Q10, and uses thereof”
3. US Patent #6,251,400: “Compositions and methods of treatment of neoplastic diseases and hypercholesterolemia with citrus Limonoids and flavonoids and Tocotrienol”
4. US Patent #6,239,114: “Compositions and methods for treatment of neoplastic diseases with combinations of Limonoids, flavonoids and Tocotrienol”
5. US Patent #6,949,261 – Compositions for diabetes treatment and prophylaxis
6. US Patent #6,946,151 – Therapeutic compositions
7. US Patent #8,936,817 – Preparation for weight loss management

Res-Q PM

1. Brusco LI, Fainstein I, Marquez M, Cardinali DP. Departamento de Fisiologia, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina. Effect of melatonin in selected populations of sleep-disturbed patients. Biol Signals Recept. 1999 Jan-Apr;8(1-2):126-31.
2. Brown G.M. Clarke Institute of Psychiatry, 250 College Street, Toronto, Ont. M5T 1R8 Canada. Light, melatonin and the sleep-wake cycle. J. Psychiatry Neurosci. (Canada), 1994, 19/5 (345-353)
3. Haimov I.; Lavie P.; Laudon M.; Herer P.; Vigder C.; Zisapel N. Sleep Laboratory, Gutwirth Building, Technion City, Haifa 32000 Israel. Melatonin replacement therapy of elderly insomniacs. Sleep (USA), 1995, 18/7 (598-603)
4. Middleton B, Arendt J, Stone BM. Chronobiology Laboratory, School of Biological Sciences, University of Surrey, Guildford, United Kingdom. Complex effects of melatonin on human circadian rhythms in constant dim light. J Biol Rhythms. 1997 Oct;12(5):467-77.
5. Donath F, Quispe S, Diefenbach K, Maurer A, Fietze I, Roots I. Institute of Clinical Pharmacology, Charite University Medical Center, Humboldt University of Berlin, Germany. Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry 2000 Mar;33(2):47-53